Of the tracked stories, 2 of 2 also mention Abbott Laboratories, the most common co-covered peer. The 39-day window averages about 0.4 stories each week. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Cologuard
Of the tracked stories, 2 of 2 also mention Abbott Laboratories, the most common co-covered peer. The 39-day window averages about 0.4 stories each week. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. At 5.5, the average consequence score sits below the same-window beat average of 5.8. We currently track 2 Healthcare stories that mention Cologuard, published between July 17, 2026 and August 24, 2026.
Stories tracked
2
Per week
0.4
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 386 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Cologuard. Shared-story counts are live from our verified record — not editorial picks.
For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.
Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Cologuard is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
